Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease.
about
TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide studyComplement contributes to inflammatory tissue destruction in a mouse model of Ross River virus-induced diseaseExpression of the C5a receptor (CD88) on granulocytes and monocytes in patients with severe sepsis.The role of the complement and the Fc gamma R system in the pathogenesis of arthritisIdentification of conformation-dependent epitopes and V gene selection in the B cell response to type II collagen in the DA rat.Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genesThe extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q.Random mutagenesis of the complement factor 5a (C5a) receptor N terminus provides a structural constraint for C5a docking.A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritisA large-scale rheumatoid arthritis genetic study identifies association at chromosome 9q33.2.Deficiency in mouse hyaluronidase 2: a new mechanism of chronic thrombotic microangiopathy.Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration.Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in miceTGF-beta-treated antigen presenting cells suppress collagen- induced arthritis through the promotion of Th2 responses.Inhibitors of C5 complement enhance vaccinia virus oncolysis.Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) diseaseMannan induces ROS-regulated, IL-17A-dependent psoriasis arthritis-like disease in mice.Identification of a potent and orally active non-peptide C5a receptor antagonist.Complement-targeted therapeuticsYes T cells, but three different T cells (alphabeta, gammadelta and NK T cells), and also B-1 cells mediate contact sensitivity.Normal pregnancy is characterized by systemic activation of the complement system.Elimination of C5aR prevents intestinal mucosal damage and attenuates neutrophil infiltration in local and remote organs.The C-type lectin of the aggrecan G3 domain activates complement.Role for complement in development of Helicobacter-induced gastritis in interleukin-10-deficient mice.A single functional group substitution in c5a breaks B cell and T cell tolerance and protects against experimental arthritis.Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation.Functional analysis of a complement polymorphism (rs17611) associated with rheumatoid arthritisMethotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis.Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.Prophylactic and therapeutic treatment with a synthetic analogue of a parasitic worm product prevents experimental arthritis and inhibits IL-1β production via NRF2-mediated counter-regulation of the inflammasomePRELP protein inhibits the formation of the complement membrane attack complex.Molecular targets in immune-mediated diseases: focus on rheumatoid arthritis.Novel C5a regulators in inflammatory disease.Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction.Genetic influences on the end-stage effector phase of arthritis.B cell-dependent T cell responses: IgM antibodies are required to elicit contact sensitivity.Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis.Required early complement activation in contact sensitivity with generation of local C5-dependent chemotactic activity, and late T cell interferon gamma: a possible initiating role of B cells.Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59
P2860
Q24657292-15F30D3E-4304-4921-9E38-E40BE129786AQ24682922-A6CB9894-05F9-4EC9-85E3-A485037BC440Q24801467-18725A16-C4CF-4009-8604-9D24C2DF73CFQ24817177-53793EF6-599A-451D-936D-531397A4FED1Q30684241-C5AB628B-FC56-42E9-A567-C9CDE1B040D3Q31017238-EA707337-D548-4177-AE51-8891685EABFFQ33220400-776DA6C4-A16C-41F2-860B-A65E1302A0EDQ33259490-986E1D67-571C-41F9-BD09-A3DBD324BA65Q33299576-D648E902-0EB8-4BC6-9D1E-CDD5977984EFQ33354118-321BA0C4-DEEA-4995-9282-E6AC4F12B561Q33422493-DDD53380-427A-4D6B-A9D3-09E54960222DQ33630007-EBEB6779-A0AE-4FA6-B604-04AEDCF94862Q33685823-9A5D12F0-5DF4-4758-9C39-83F0D6836C18Q33687307-CD7553DA-F07B-466C-A07C-CC21F693E76FQ33751381-2523C530-5587-4333-8D49-B6AA043B4B9AQ33768177-43BA3D02-B065-46D4-9E41-9E873D397A38Q33769083-6EC515C4-409F-429E-BC8D-88AF47DC35BDQ34144256-1A4EE339-F512-4B3C-ABDE-1BACC86A772DQ34154819-5E5EE436-AAE5-4AC5-94EF-D1B85AF35C9CQ34255011-46B096FA-B46F-4096-8C33-1A454A185431Q34352839-BB3D99F3-D158-4248-B620-1B7676C0367CQ34499492-A0E7A57F-879C-4053-87D8-D3ADB37F1F3EQ34509114-10976526-69B5-42F9-BD76-8D7FF1F2EBAEQ34676309-CDFAD405-F33D-4958-BBA7-28889CCA9F91Q34940884-528C1415-41E5-4EAE-B893-B6136BB94E3FQ34998962-661F141D-2469-4970-9418-F8A303F1B19EQ35095565-B273F7D2-87EC-4831-AA8D-963BBDDF4D59Q35199125-1B2A73FB-F13B-4B76-9BD0-959D33485B1CQ35555358-7B3B9544-DA88-44D9-A3EF-C38AF4EEBBE2Q35555743-41C5863A-FBF9-4407-A120-4B9604AFD860Q35694891-82E9BBCA-8D57-4263-88D3-3E9149779342Q35868224-DC1FD8EB-303B-41EB-9501-6644698749FEQ35911103-B1220597-049F-4A7E-98A5-E20864F57958Q36196446-C64AF7E7-EDAA-4495-BDFB-C8E9671F5C20Q36228832-842977E6-E808-49B6-955C-C05E27204CA0Q36369446-BFB818CB-B07E-467E-9ADE-02F2B0122633Q36371044-77351768-BB04-42DA-9928-DE197BC0D0CFQ36371879-F63440E5-6A03-409F-A232-2EA80FE6A677Q36380633-13DC032A-1851-4D5A-AF5F-85EC35E6A9C3Q36380744-E2B3B8B8-275D-4BF0-A60C-A67C06224EA9
P2860
Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease.
description
1995 nî lūn-bûn
@nan
1995 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Anti-C5 monoclonal antibody th ...... eliorates established disease.
@ast
Anti-C5 monoclonal antibody th ...... eliorates established disease.
@en
type
label
Anti-C5 monoclonal antibody th ...... eliorates established disease.
@ast
Anti-C5 monoclonal antibody th ...... eliorates established disease.
@en
prefLabel
Anti-C5 monoclonal antibody th ...... eliorates established disease.
@ast
Anti-C5 monoclonal antibody th ...... eliorates established disease.
@en
P2093
P2860
P356
P1476
Anti-C5 monoclonal antibody th ...... eliorates established disease.
@en
P2093
P2860
P304
P356
10.1073/PNAS.92.19.8955
P407
P577
1995-09-01T00:00:00Z